JPMorgan Chase & Co. Acquires 92,014 Shares of DaVita Inc. (NYSE:DVA)

JPMorgan Chase & Co. grew its holdings in shares of DaVita Inc. (NYSE:DVA) by 17.8% during the third quarter, Holdings Channel.com reports. The institutional investor owned 609,076 shares of the company’s stock after purchasing an additional 92,014 shares during the quarter. JPMorgan Chase & Co.’s holdings in DaVita were worth $99,846,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of the stock. MML Investors Services LLC boosted its stake in DaVita by 1.3% during the third quarter. MML Investors Services LLC now owns 5,300 shares of the company’s stock worth $869,000 after acquiring an additional 68 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of DaVita by 1.5% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,759 shares of the company’s stock valued at $776,000 after buying an additional 70 shares during the period. Wedmont Private Capital increased its position in DaVita by 4.4% in the 3rd quarter. Wedmont Private Capital now owns 1,776 shares of the company’s stock valued at $280,000 after buying an additional 75 shares in the last quarter. First Trust Direct Indexing L.P. raised its stake in DaVita by 2.9% during the 3rd quarter. First Trust Direct Indexing L.P. now owns 3,051 shares of the company’s stock worth $500,000 after buying an additional 86 shares during the period. Finally, Nomura Asset Management Co. Ltd. grew its stake in DaVita by 0.4% in the third quarter. Nomura Asset Management Co. Ltd. now owns 28,790 shares of the company’s stock valued at $4,720,000 after acquiring an additional 117 shares during the period. Institutional investors and hedge funds own 90.12% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on the company. Truist Financial increased their target price on DaVita from $165.00 to $175.00 and gave the stock a “hold” rating in a report on Monday, October 7th. Barclays raised their price objective on shares of DaVita from $150.00 to $164.00 and gave the company an “equal weight” rating in a research note on Thursday, October 31st. One analyst has rated the stock with a sell rating, three have given a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat, DaVita has an average rating of “Hold” and a consensus price target of $161.80.

DaVita Trading Up 0.2 %

NYSE DVA opened at $149.82 on Friday. The company has a current ratio of 1.37, a quick ratio of 1.33 and a debt-to-equity ratio of 15.78. The business has a fifty day simple moving average of $155.19 and a 200 day simple moving average of $151.50. DaVita Inc. has a 12 month low of $103.40 and a 12 month high of $169.51. The firm has a market capitalization of $12.29 billion, a P/E ratio of 16.16, a PEG ratio of 0.86 and a beta of 0.90.

DaVita (NYSE:DVA) last announced its earnings results on Tuesday, October 29th. The company reported $2.59 EPS for the quarter, missing the consensus estimate of $2.76 by ($0.17). DaVita had a net margin of 6.53% and a return on equity of 88.18%. The firm had revenue of $3.26 billion during the quarter, compared to analysts’ expectations of $3.25 billion. During the same quarter in the prior year, the company earned $2.85 EPS. The business’s revenue for the quarter was up 4.6% on a year-over-year basis. On average, analysts predict that DaVita Inc. will post 9.71 EPS for the current fiscal year.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.